ProMIS Neurosciences (PMN) Other Accumulated Expenses (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Other Accumulated Expenses came in at $99840.0 in Q1 2026, up 183.98% YoY from $35158.0 in Q1 2025, and up 25.2% on a QoQ basis from $79743.0 in Q4 2025.
ProMIS Neurosciences (PMN) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Other Accumulated Expenses data on file, last reported at $99840.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 183.98% year-over-year to $99840.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99840.0 (up 183.98% YoY) and the FY2025 annual result came in at $79743.0, up 0.58% from the prior year.
- Other Accumulated Expenses advanced to $99840.0 in Q1 2026, from $79743.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $577594.0 in Q3 2023 to a low of $3980.0 in Q2 2023.
- A 5-year average of $132017.1 and a median of $79513.0 in 2024 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses sank 98.36% — and 2024, when it surged 1652.36%.
- Tracing PMN's Other Accumulated Expenses over 5 years: stood at $178330.0 in 2022, then sank by 84.16% to $28249.0 in 2023, then surged by 180.66% to $79283.0 in 2024, then rose by 0.58% to $79743.0 in 2025, then grew by 25.2% to $99840.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $99840.0 (Q1 2026), $79743.0 (Q4 2025), and $72025.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79,897.00 |
| Mar 31, 2026 | 99,840.00 |
| Dec 31, 2025 | 79,743.00 |
| Sep 30, 2025 | 72,025.00 |
| Jun 30, 2025 | 4,276.00 |
| Mar 31, 2025 | 35,158.00 |
| Dec 31, 2024 | 79,283.00 |
| Sep 30, 2024 | 157,134.00 |
| Jun 30, 2024 | 69,744.00 |
| Mar 31, 2024 | 40,209.00 |
| Dec 31, 2023 | 28,249.00 |
| Sep 30, 2023 | 577,594.00 |
| Jun 30, 2023 | 3,980.00 |
| Mar 31, 2023 | 264,609.00 |
| Dec 31, 2022 | 178,330.00 |
| Sep 30, 2022 | 179,228.00 |
| Jun 30, 2022 | 242,872.00 |
| Dec 31, 2021 | 64,047.00 |